开发选择性类固醇激素受体调节剂有望成为未来防治骨质疏松药物的研究方向。
To develop a new selective steroid receptor modulator is one of the targets in future study to treat osteoporosis.
关键是所谓选择性雄激素受体调节剂，或行动情报处。
The key is something called a selective androgen receptor modulator, or SARM.
目的合成选择性雌激素受体调节剂盐酸雷洛昔芬。
Objective To synthesize raloxifene hydrochloride, which is a selective estrogen receptor modulator.
目的选择性雌激素受体调节剂对去势大鼠松质骨、皮质骨骨密度的影响。
AIM to discuss the influence of selective estrogen receptor modulator (SERM) on bone mineral density loss in cancellated bone and compact bone of ovariectomized rats.
该试剂定义新一亚类化合物，它们是选择性雄激素受体调节剂(SARM)。
The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM).
目的：探讨选择性雌激素受体调节剂雷洛昔芬对去卵巢大鼠血压、血脂、纤维蛋白原和雌激素受体的作用。
Objective: To investigate the effect of raloxifene, a selective estrogen receptor modulator, on blood pressure, lipid, fibrinogen and estrogen receptor in ovariectomized rats.
结构式(i)的化合物是组织选择性的雄激素受体(AR)调节剂。
Compounds of structural formula (I) are modulators of the androgen receptor (ar) in a tissue selective manner.
雷洛昔芬(Evista)是一种选择性雌激素受体调节剂，可以用来防治骨质疏松症。
C. Raloxifene (Evista) is a selective estrogen receptor modulator. It is available for prevention and treatment of osteoporosis.
选择性雌激素受体调节剂是一类在不同的组织细胞中对雌激素受体发挥不同调节作用的化合物，用于治疗绝经后妇女的骨质疏松和乳腺癌等。
Selective estrogen receptor modulators (SERMs) are kinds of compounds that exert different biological effects on er in different tissues and can be used in the tr.
综述近几年上市或开发中的雌激素受体调节剂类药物，主要包括选择性雌激素受体调节剂和纯抗雌激素药物。
The estrogen receptor modulator drugs launched or developed in recent years were reviewed, mainly including selective estrogen receptor modulators and pure antiestrogen.
选择性雌激素受体调节剂使用者症状出现的比值比为1.39 (95%CI 1.22 - 1.59)，而使用非处方激素的妇女1.37 (9 5% CI 1.16 - 1.62)。
For GERD symptoms, or was 1.39 (95% CI, 1.22-1.59) for current SERM users and 1.37 (95% CI, 1.16-1.62) for women currently using OTC hormone preparations.
选择性雌激素受体调节剂使用者症状出现的比值比为1.39 (95%CI 1.22 - 1.59)，而使用非处方激素的妇女1.37 (9 5% CI 1.16 - 1.62)。
For GERD symptoms, or was 1.39 (95% CI, 1.22-1.59) for current SERM users and 1.37 (95% CI, 1.16-1.62) for women currently using OTC hormone preparations.
应用推荐